Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
How Important Are Ozempic and Wegovy to Novo Nordisk's Business?
06:15am, Thursday, 08'th Feb 2024
Novo Nordisk's obesity sales more than doubled last quarter. Ozempic and Wegovy account for a significant part of total revenue.
Novo Nordisk CEO on Catalent, Ozempic and Wegovy
02:06pm, Wednesday, 07'th Feb 2024
Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic. F
Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks
02:48pm, Tuesday, 06'th Feb 2024
The trillion-dollar market valuation club is currently dominated by the tech sector. Saudi Aramco is the sole exception.
Healthy Returns: Novo Nordisk, Eli Lilly are tackling weight loss drug supply woes
02:13pm, Tuesday, 06'th Feb 2024
Novo Nordisk and Eli Lilly are working to increase supply of their popular weight loss drugs. Meanwhile, the implantable neurotechnology field is heating up.
Novo Nordisk acquisition of Catalent production sensible, analysts say
02:08pm, Tuesday, 06'th Feb 2024
Novo Nordisk (NYSE:NVO)'s takeover of three production sites through the acquisition of Catalent Inc (NYSE:CTLT) is a sensible move, analysts say, and will help meet demand for its flagship weight los
Bio-pharma services are key to our strategy: Novo Holdings CEO
10:00am, Tuesday, 06'th Feb 2024
Kasim Kutay, CEO of Novo Holdings, discusses Novo Holdings acquisition of U.S.-based medicines manufacturer Catalent.
Novo Holdings invests in hospital chain Manipal in India
03:20am, Tuesday, 06'th Feb 2024
Novo Holdings, the holding company of Novo Nordisk , said on Tuesday it was investing in Indian private hospital chain Manipal Hospitals, its largest investment in Asia to date.
Why Novo Nordisk Stock Crushed the Market on Monday
06:07pm, Monday, 05'th Feb 2024
Its controlling shareholder has agreed to acquire U.S. contract manufacturer Catalent. The all-cash transaction's enterprise value is $16.5 billion.
Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B
01:36pm, Monday, 05'th Feb 2024
Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.
Novo Nordisk Makes the Latest Big Pharma Deal. Why More Are Coming.
12:27pm, Monday, 05'th Feb 2024
Big drug companies have substantial free cash flow from older, cash-cow drugs, manageable debt burdens, and investor pressure to find new growth opportunities.
Novo Holdings Buyout Sends Catalent Stock Surging
11:07am, Monday, 05'th Feb 2024
The shares of pharmaceutical concern Catalent Inc (NYSE:CTLT) are surging today, after news that Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is purchasing the company for $11.5
Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal
11:05am, Monday, 05'th Feb 2024
Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.
Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk
10:57am, Monday, 05'th Feb 2024
Catalent (NYSE: CTLT ) stock is climbing higher on Monday after the company agreed to sell itself to Novo Nordisk (NYSE: NVO ) parent Novo Holdings for $16.5 billion. The transaction will have Novo Ho
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
09:19am, Monday, 05'th Feb 2024
Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.
Catalent surges on $16.5 billion takeover by Novo Nordisk shareholder
07:46am, Monday, 05'th Feb 2024
Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)'s controlling shareholder was to buy the firm for US$16.5 billion.
